Auto-immune Diseases

Sep 19, 2023 | academic.oup.com | Le Kremlin-Bicêtre |Auto-immune Diseases |Le Kremlin Bicêtre

To investigate whether the efficacy and safety data from drug-registration trials can be extrapolated to real-life RA patients receiving RTX. The AIR-PR registry is a French multicentre, prospective cohort of RA patients treated with RTX in a real-life setting. We compared treatment responses at 12 months and serious AEs between eligible and non-eligible patients, by retrieving the eligibility criteria of the three rituximab-registration trials.